heart failure
Conditions
Interventions
The Control Group(Conventional drug therapy):Conventional drug therapy (valsartan + metoprolol succinate + spironolactone + Furosemide)
The Treatment Group(Conventional drug therapy + abdominal acupuncture):Conventional drug therapy (valsartan + metoprolol succinate + spironolactone + Furosemide)+ abdominal acupuncture
DZ01ZL01
Sponsors
Beijing Mentougou Hospital of Traditional Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: (1) Patients with newly diagnosed chronic heart failure or previously diagnosed heart failure who are currently under drug control; (2) NYHA cardiac function class ?-?; (3) Sign the informed consent and volunteer to participate in the research project; (4) Persons aged between 18 and 80.
Exclusion criteria
Exclusion criteria: (1) Acute heart failure, cardiogenic shock, severe arrhythmia, complete mode block, obstructive cardiomyopathy, severe valvular heart disease, stenosis pericarditis, pulmonary embolism, uncontrolled hypertension; (2) Patients with severe liver insufficiency and severe renal insufficiency; (3) pregnant and lactating women; (4) Severe heart failure, cardiac function grade IV; (5) mental disorders and cognitive impairment; (6) Unwilling to cooperate with the treatment process of this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| NYHA Heart Function; | — |
Secondary
| Measure | Time frame |
|---|---|
| 6 minute walk test;NT-proBNP;TCM syndrome integration;C-MLHFQ; | — |
Countries
China
Contacts
Public ContactLi Yuanguan
Outcome results
None listed